Glenmark gets FDA nod for calcipotriene ointment
This article was originally published in Scrip
Glenmark Generics, a US subsidiary of India's Glenmark, has received final approval from the US FDA for calcipotriene ointment 0.005%, a generic version of Leo Pharmaceuticals' plaque psoriasis treatment, Dovonex. Leo Pharmaceuticals marketed Dovonex ointment from December 1993 until April 2007, when the product was discontinued due to lack of commercial viability, Glenmark said. Leo still markets a line of Dovonex products including a cream and a topical solution. Dovonex reported peak sales of about $93 million in 2006.
You may also be interested in...
Deal news from Strides Pharma, Pharmaceutics Intl., Cipla, Wanbury, AstraZeneca, Syntekabio, Arctoris, Mundipharma, Samsung Bioepis…
Eisai and partner Sun to take lorcaserin off the Indian market. It remains to be seen whether the Japanese firm sees merit in pursuing a simmering patent infringement suit against Dr Reddy’s, which may need to review its own plans for lorcaserin.